Skip to main content

Advertisement

Table 3 Linear regression analysis on health-related quality of life outcomes in 252 patients with systemic lupus erythematosus in regard with disease activity age, sex and disease duration

From: Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)

Outcomes Predictors  
SELENA-SLEDAI, unadjusted (N = 252) SLEDAI, adjusted for age, sex and disease duration (N = 225)
Difference in SF-36 score for a 1-point increase in SELENA-SLEDAI 95%-C.I. p Difference in SF-36 score for a 1-point increase in SELENA-SLEDAI 95%-C.I. p
Physical function −0.57 (−1.05, −0.10) 0.019 −0.66 (−1.12, −0.19) 0.006
Role physical −1.86 (−2.63, −1.09) <0.001 −1.85 (−2.63, −1.07) <0.001
Bodily pain −1.16 (−1.68, −0.64) <0.001 −1.27 (−1.79, −0.74) <0.001
General health −0.31 (−0.70, 0.08) 0.12 −0.27 (−0.67, 0.13) 0.19
Vitality −0.48 (−0.86, −0.10) 0.014 −0.46 (−0.86, −0.07) 0.022
Social function −0.72 (−1.19, −0.25) <0.001 −0.71 (−1.20, −0.22) 0.005
Role emotional −1.92 (−2.73, −1.11) <0.01 −1.86 (−2.70, −1.01) <0.001
Mental health −0.48 (−0.84, −0.13) 0.008 −0.46 (−0.81, −0.11) 0.011
Mental component summary −0.31 (−0.50, −0.12) 0.002 −0.34 (−0.53, −0.15) <0.001
Physical component summary −0.36 (−0.57, −0.15) 0.001 −0.33 (−0.55, −0.11) 0.003
  1. SELENA-SLEDAI Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)